Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2022; 28(26): 3164-3176
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3164
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3164
Bifidobacterium infantis regulates the programmed cell death 1 pathway and immune response in mice with inflammatory bowel disease
Lin-Yan Zhou, Ying Xie, Yan Li, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Zhou LY obtained funding, processed the samples, analyzed the raw data, and wrote manuscript; Xie Y processed the samples, obtained and managed data; Li Y conceived the study protocol, critically revised the manuscript, and approved the final version.
Supported by the Doctoral Start-up Foundation of Liaoning Province , No. 2021-BS-114 .
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board at Shengjing Hospital of China Medical University.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals, No. 2017PS353K.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Li, PhD, Chief Doctor, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 36 Sanhao Road, Heping District, Shenyang 110004, Liaoning Province, China. liy@sj-hospital.org
Received: December 6, 2021
Peer-review started: December 6, 2021
First decision: January 8, 2022
Revised: January 12, 2022
Accepted: June 16, 2022
Article in press: June 16, 2022
Published online: July 14, 2022
Peer-review started: December 6, 2021
First decision: January 8, 2022
Revised: January 12, 2022
Accepted: June 16, 2022
Article in press: June 16, 2022
Published online: July 14, 2022
Core Tip
Core Tip: Bifidobacterium infantis (B. infantis) can be used as a therapeutic agent to treat inflammatory bowel disease. It regulates the intestinal microbiota, alleviates inflammation, and regulates the immune response. We found that B. infantis increases the expression of forkhead box protein 3 (Foxp3) and the proliferation of Foxp3+ T cells, and activates the programmed cell death 1 (PD-1)/ PD ligand 1 pathway.